dose pharmacokinetic

Related by string. * DO Se . Doses . DOSE . DOSES . Dose : mg kg dose . tolerated dose MTD . label dose escalation . dose escalation study . multiple ascending dose / Pharmacokinetics . Pharmacokinetic . pharmacokinetics : pharmacokinetics PK . pharmacokinetic PK . safety tolerability pharmacokinetics . safety tolerability pharmacokinetic . favorable pharmacokinetic profile * *

Related by context. Frequent words. (Click for all words.) 59 Phase 1a 59 dose escalation study 59 placebo controlled clinical 59 placebo controlled randomized 59 single ascending dose 59 phase IIa 58 Phase 1b 58 RGB # 58 Phase 2b study 58 SCH # 58 Phase 2a clinical 58 placebo controlled studies 57 double blinded placebo 57 randomized #:# 57 Phase IIa clinical 57 dose escalation trial 57 Phase Ib 57 dose regimens 57 Phase Ia 57 safety tolerability pharmacokinetics 57 AZX# 57 multiple ascending dose 57 Phase 2a 56 active comparator 56 Phase 1b clinical 56 vitro experiments 56 Phase 2b clinical 56 blinded placebo controlled 56 Phase 1b trial 55 pharmacodynamics 55 phase IIb 55 nab paclitaxel 55 prospective randomized controlled 55 phase 2a 55 blind randomized controlled 55 dose cohorts 55 subcutaneous injections 55 multicenter randomized double 55 dosing regimens 55 randomized Phase III 55 Sym# 55 Azedra 55 administered subcutaneously 54 Phase IIa 54 MIRCERA 54 Phase 2b trial 54 Pivotal Phase III 54 blind randomized placebo 54 multicenter randomized 54 Phase IIb clinical 54 Phase IIb 54 HGS ETR1 53 ALN TTR# 53 nitazoxanide 53 Pharmacokinetic 53 prospective observational 53 hepatitis C HCV 53 HCV infected 53 randomized placebo controlled 53 pharmacokinetic studies 53 label dose escalation 53 intravenous dose 53 Phase 2a trial 53 events SAEs 53 Phase IIa clinical trials 53 HER2 positive metastatic breast 53 placebo controlled trials 53 RDEA# 53 glufosfamide 53 placebo controlled 53 Allovectin 7 R 53 randomized controlled clinical trials 52 secondary efficacy endpoints 52 Amrubicin 52 ICA # 52 PRX # 52 IIa clinical trial 52 PRECiSE 52 romidepsin 52 Phase 2b 52 pharmacodynamic 52 BAY #-# 52 Phase III randomized 52 Laquinimod 52 randomized clinical 52 Phase IIa trial 52 NRTI 52 tgAAC# 52 Cloretazine R VNP#M 52 thymalfasin 52 Preclinical studies 52 vitro studies 52 pharmacokinetic profiles 52 MAP# 52 double blind placebo 51 ISIS # 51 temsirolimus 51 safety tolerability 51 peginterferon alfa 2b 51 mg kg dose 51 pharmacokinetic

Back to home page